| Literature DB >> 31910389 |
Patrick Brown1, Hiroto Inaba2, Colleen Annesley3, Jill Beck4, Susan Colace5, Mari Dallas6, Kenneth DeSantes7, Kara Kelly8, Carrie Kitko9, Norman Lacayo10, Nicole Larrier11, Luke Maese12, Kris Mahadeo13, Ronica Nanda14, Valentina Nardi15, Vilmarie Rodriguez16, Jenna Rossoff17, Laura Schuettpelz18, Lewis Silverman19, Jessica Sun11, Weili Sun20, David Teachey21, Victor Wong22, Gregory Yanik23, Alyse Johnson-Chilla24, Ndiya Ogba24.
Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.Entities:
Mesh：
Year: 2020 PMID： 31910389 DOI： 10.6004/jnccn.2020.0001
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908